Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:18:49.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the Last Update Posted date for the study record related to the clinical trial evaluating the safety and efficacy of nivolumab, ipilimumab, and bicalutamide in HER2-negative breast cancer patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:13:06.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of 'Participation Criteria,' explaining that researchers look for people who fit specific eligibility criteria, such as general health condition or prior treatments. The new text also provides an example of eligibility criteria and directs users to 'Learn About Studies' for more information on clinical research.
    Difference
    45%
    Check dated 2024-05-22T19:50:57.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:39:07.000Z thumbnail image

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.